North America to maintain the lion’s share by 2026

By -

 Increase in demand for LFIA based rapid test kits across geographies along with rise in target population is majorly driving the market growth. Furthermore, surge in prevalence of infectious disease along with rise in demand for rapid test is expected to boost the requirement of LFIA based rapid test in the coming years. 

The global LFIA based rapid test market size was valued at $4.72 billion in 2018, and is expected to reach $8.50 billion by 2026, growing at a CAGR of 7.6% from 2019 to 2026. 

The infectious disease segment to retain its dominance till 2026-

Based on application, the infectious disease segment contributed to more than four-fifths of the global lateral flow immunoassay based rapid test market share in 2018, and is expected to rule the roost throughout the study period. Increase in initiatives by the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services, Food and Drug Administration, and National Institutes of Health (NIH) for the diagnosis of infectious diseases contributes toward the market growth. The same segment would also cite the fastest CAGR of 7.8% by the end of 2026.

The competitive assay segment to lead the trail during the forecast period-

Based on technique type, the competitive assay segment held the major share in 2018, generating nearly three-fifths of the global lateral flow immunoassay based rapid test market. Competitive immunoassays are widely used in the market, as these require only a small amount of antibody, higher flexibility, and sensitivity. The multiplex detection assay segment, on the other hand, would grow at the fastest CAGR of 9.0% during the estimated period. This is because it saves both time & precious sample by combining the detection of multiple analytes into a single reaction that reduces workflow and sample volume problems.

North America to maintain the lion’s share by 2026-

Based on geography, North America accounted for more than two-fifths of the global lateral flow immunoassay based rapid test market revenue in 2018, and is predicted to dominate till 2026. Rise in prevalence of various diseases such as influenza, HIV, and cancer; increase in number of drug screening procedures; and presence of leading players in the market fuel the market growth in the province. At the same time, the region across Asia-Pacific would register the fastest CAGR of 9.2% during 2019–2026. This is attributed to high population base, increase in disposable income, and rise in awareness about LFIA based rapid tests in the region.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/6228

Key market players-

  • Becton
  • F. Hoffmann-La Roche AG (Roche Diagnostics)
  • Dickinson and Company
  • Thermo Fisher Scientific
  • Qiagen N.V.
  • Bio-rad Laboratories, Inc.
  • Abbott Laboratories (Alere Inc.)
  • Danaher Corporation (Cepheid, Inc.)
  • Hologic, Inc.
  • Quidel Corporation
  • Biomerieux SA

Comments

Post a Comment

Popular posts from this blog

Global Cancer pain market is segmented based on drug type, disease indication, and region.

By -
According to a new report published by Allied Market Research, titled, "Cancer Pain Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2018 - 2025,"  the global cancer pain market was valued at $5,285 million in 2017, and is expected to reach $7,545 million by 2025, growing at a CAGR of 4.5% from 2018 to 2025. Download the Sample Report @  https://www.alliedmarketresearch.com/request-sample/5123?utm_source=Blogger&utm_medium=Niranjan Cancer pain is chronic in nature and is commonly associated with cancer. It results from tissue damage, either due to the disease itself or due to different treatments such as chemotherapy, radiotherapy, or surgery. Cancer pain drugs are expected to exhibit significant market growth during the forecast period due to growth in demand for the drugs, surge in prevalence of cancer across the globe, increase in number of R&D activities to develop ideal cancer pain medications, and rise in the unmet nee...
Read more

U.S. was the largest country market in 2015, and is projected to maintain its lead until 2022.

By -
Image
  Surge in usage of wireless monitoring devices and increase in population of aging people across the globe drive the growth of the global patient monitoring devices market. However, high cost associated with patient monitoring devices is anticipated to restrain the market growth. Furthermore, increasing technological advancements are expected to provide new opportunities during the forecast period. The  Patient Monitoring Devices Market  generated $25.76 billion in 2019, and is estimated to reach $44.86 billion by 2027, registering a CAGR of 4.4% from 2020 to 2027. Based on product type, the cardiac monitoring devices segment contributed to the largest share in 2019, accounting for more than one-fourth of the total share, and is estimated to maintain its dominant position during the forecast period. However, the remote patient monitoring devices segment is estimated to portray the highest CAGR of 6.3% during the forecast period. Based on end-user, the hospitals segment a...
Read more